<HTML>
<HEAD>
<TITLE>Form S-8 for Spectrum</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>


<P align="center"><FONT size="2"><B>As filed with the Securities and
Exchange Commission on June&nbsp;24, 2003</B>
</FONT>


<div align="right"><FONT size="2"><B>Registration No.&nbsp;333-_________</B>
</FONT></div>

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">







<P align="center"><FONT size="4"><B>SECURITIES AND EXCHANGE COMMISSION
</B></FONT>


<DIV align="center"><FONT size="3"><B>WASHINGTON, D.C. 20549</B>
</FONT></DIV>


<DIV align="center"><HR align="center" size="1" width="15%" noshade></DIV>


<P align="center"><FONT size="5"><B>FORM S-8
</B></FONT>


<DIV align="center"><FONT size="3"><B>REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933</B>
</FONT></DIV>


<DIV align="center"><HR align="center" size="1" width="15%" noshade></DIV>


<P align="center"><FONT size="6"><B>SPECTRUM PHARMACEUTICALS, INC.
</B></FONT>


<DIV align="center"><FONT size="2"><B>(Exact Name of Registrant as Specified in Its Charter)</B>
</FONT></DIV>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2"><B>Delaware</B></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<B>93-079187</B></FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2"><B>(State or Other Jurisdiction of<BR>
Incorporation or Organization)</B></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<B>(I.R.S. Employer<BR>
Identification Number)</B></FONT></TD>
</TR>
</TABLE>
</CENTER>

<DIV align="center"><HR align="center" size="1" width="15%" noshade></DIV>


<DIV align="center"><FONT size="2"><B>157 Technology Dr.<br>
Irvine, California 92618</B>
</FONT></DIV>


<DIV align="center"><FONT size="2">(Address of Principal Executive Offices including Zip Code)
<HR align="center" size="1" width="15%" noshade>
</FONT></DIV>


<P align="center"><FONT size="2"><B>SPECTRUM PHARMACEUTICALS, INC.</B>
</FONT>


<P align="center"><FONT size="2"><B>AMENDED AND RESTATED</B>
</FONT>


<P align="center"><FONT size="2"><B>1997 STOCK INCENTIVE PLAN</B>
</FONT>


<P align="center"><FONT size="2"><B>(Full Title of the Plan)</B>
</FONT>


<P align="center"><HR align="center" size="1" width="15%" noshade>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2"><B>Rajesh C. Shrotriya</B></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<B>Copy to:</B></FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2"><B>Chief Executive Officer and President<BR>
Spectrum Pharmaceuticals, Inc.<BR>
157 Technology Drive</B></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<B>Alan W. Pettis<BR>
Latham &#038; Watkins LLP<BR>
650 Town Center Drive, Twentieth Floor</B></FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2"><B>Irvine, California 92618<BR>
(949)&nbsp;788-6700</B></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">
<B>Costa Mesa, California 92626<BR>
(714)&nbsp;540-1235</B></FONT></TD>
</TR>
</TABLE>
</CENTER>

<P align="center"><HR align="center" size="1" width="15%" noshade>


<div align="center"><FONT size="2"><B>(Name, Address, Including Zip Code, and Telephone Number,<BR>
Including Area Code, of Agent for Service)</B>
</FONT></div>


<div align="center"><HR align="center" size="1" width="15%" noshade></div>


<P align="center"><FONT size="2"><B>CALCULATION OF REGISTRATION FEE</B>
</FONT>

<HR size="1" noshade>




<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Proposed</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Proposed</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Maximum</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Amount</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Maximum</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Aggregate</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Amount of</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><FONT size="1"><B>Title of Securities to</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>to be</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Offering Price</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Offering</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Registration</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><FONT size="1"><B>be Registered</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Registered<sup>(1)(2)</sup></B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Per Share<sup>(3)</sup></B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Price<sup>(3)</sup></B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center" colspan="3"><FONT size="1"><B>Fee</B></FONT></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD colspan="3"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD colspan="3"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD colspan="3"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD colspan="3"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px"><FONT size="2">Common stock par
value $0.001 per
share</FONT></DIV></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" align="center"><FONT size="2">1,199,000 shares</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">$</FONT></TD>
    <TD align="right"><FONT size="2">16.165</FONT></TD>

    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
        <TD><FONT size="2">$</FONT></TD>
    <TD align="center"><FONT size="2">19,381,400</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">$</FONT></TD>
    <TD align="center"><FONT size="2">1,567.96</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
</TABLE>
</CENTER>

<P>
<HR size="1" width="18%" align="left" noshade>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="1%" align="left" nowrap><FONT size="2">(1)</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="96%"><FONT size="2">The Spectrum Pharmaceuticals, Inc. Amended and Restated 1997 Stock
Incentive Plan authorizes the issuance of an aggregate of 1,219,000
shares, par value $0.001 per share, of the Registrant&#146;s common stock, of
which 1,199,000 shares are being registered hereunder and 20,000 of which
have been previously registered.</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="1%" align="left" nowrap><FONT size="2">(2)</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="96%"><FONT size="2">In the event of a stock split, stock dividend, or similar transaction
involving the Registrant&#146;s common stock, in order to prevent dilution, the
number of shares registered hereby shall automatically be increased to
cover the additional shares in accordance with Rule&nbsp;416(a) under the
Securities Act of 1933.</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="1%" align="left" nowrap><FONT size="2">(3)</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="96%"><FONT size="2">Estimated solely for the purpose of calculating the registration fee
pursuant to Rules&nbsp;457(c) and 457(h) under the Securities Act of 1933 based
on the actual exercise price of options previously granted and the average of the high and low sales price of the Registrant&#146;s common
stock on the Nasdaq SmallCap Market on June&nbsp;23, 2003 for the
remaining balance not previously granted.</FONT></TD>
</TR>
</TABLE>

<P align="center"><FONT size="2"><B>Proposed issuances to commence as soon after the effective date of the Registration<BR>
Statement as practicable.</B>
</FONT>


<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">




<P align="center"><FONT size="2">&nbsp;</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>




<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">PART I</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">PART II</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#004">Item&nbsp;4. Description of Securities</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#005">Item&nbsp;6. Indemnification of Directors and Officers.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#006">Item&nbsp;8. Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#007">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#008">POWER OF ATTORNEY</A></TD></TR>
<TR><TD colspan="9"><A HREF="#009">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="a90880exv5w1.htm">EXHIBIT 5.1</A></TD></TR>
<TR><TD colspan="9"><A HREF="a90880exv23w2.htm">EXHIBIT 23.2</A></TD></TR>
<TR><TD colspan="9"><A HREF="a90880exv23w3.htm">EXHIBIT 23.3</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "PART I" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center"><FONT size="2"><B>PART I</B>
</FONT>

<!-- link1 "INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="center"><FONT size="2"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not filing or including in this Form&nbsp;S-8 the information called for
in Part I of Form&nbsp;S-8 (by incorporation by reference or otherwise) in
accordance with the rules and regulations of the Securities and Exchange
Commission.
</FONT>

<!-- link1 "PART II" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center"><FONT size="2"><B>PART II</B>
</FONT>

<!-- link1 "INFORMATION REQUIRED IN THE REGISTRATION STATEMENT" -->
<DIV align="left"><A NAME="003"></A></DIV>
<P align="center"><FONT size="2"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B>
</FONT>


<P align="left"><FONT size="2"><B>Registration of Additional Securities</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Amended and Restated 1997 Stock Incentive Plan authorizes the issuance
of an aggregate of 1,219,000 shares of our common stock. We have previously
registered 20,000 shares (as adjusted to reflect a 25-for-1 reverse split of
our outstanding common stock that we effected on September&nbsp;6, 2002) issuable
under the Plan by a registration statement on Form&nbsp;S-8 filed with the
Securities and Exchange Commission on June&nbsp;30, 1997, Registration No.
333-30345. Under this registration statement, we are registering an additional
1,199,000 shares of our common stock issuable under the Plan. The contents of
the registration statement filed on June&nbsp;30, 1997, are incorporated by
reference herein to the extent not modified or superseded thereby or by any
subsequently filed document that is incorporated by reference herein or
therein.
</FONT>


<P align="left"><FONT size="2"><B>Experts</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of the Company as of December&nbsp;31,
2002 and for the year ended December&nbsp;31, 2002, incorporated by reference in
this registration statement have been audited by Kelly &#038; Company, independent
public accountants, as indicated in their report with respect thereto, and are
included herein in reliance upon the authority of said firm as experts in
giving said report.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of the Company as of December&nbsp;31,
2001 and for the two years ended December&nbsp;31, 2001 incorporated by reference in
this registration statement have been audited by Arthur Andersen LLP,
independent public accountants, as indicated in their report with respect
thereto, and are included herein in reliance upon the authority of said firm as
experts in giving said report. Arthur Andersen LLP has not consented to the
inclusion of their report in the registration statement, and in reliance upon
Rule&nbsp;437a of the Securities Act, we have not therefore filed their consent.
Because Arthur Andersen LLP has not consented to the inclusion of their report
in the registration statement, it may become more difficult for you to seek
remedies against Arthur Andersen LLP in connection with any material
misstatement or omission that may be contained in our consolidated financial
statements and schedules for such periods. In particular, and without
limitation, you will not be able to recover against Arthur Andersen LLP under
Section&nbsp;11 of the Securities Act for any untrue statement of a material fact
contained in the financial statements audited by Arthur Andersen LLP or any
omission of a material fact required to be statement in those financial
statements.
</FONT>

<!-- link2 "Item&nbsp;4. Description of Securities" -->
<DIV align="left"><A NAME="004"></A></DIV>

<P align="left"><FONT size="2"><B>Item&nbsp;4. Description of Securities</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>The following summary of the terms of our common stock does not purport to
be complete and is subject to and qualified in its entirety by reference to our
Charter and Bylaws, copies of which are on file with the Securities and
Exchange Commission.</I>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have authority to issue 50,000,000 shares of common stock, $.001 par
value per share. As of June&nbsp;13, 2003, we had 3,108,100 shares of common stock
outstanding, held of record by approximately 377 stockholders.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Terms</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock are entitled to one vote per share on all
matters to be voted upon by the stockholders. The holders of common stock are
not entitled to cumulative voting rights with respect to election of directors,
and as a consequence, minority stockholders will not be able to elect directors
on the basis of their shares alone. Our board of directors is divided into
three classes, with the term of each class expiring every third year at the
annual meeting of stockholders. The number of directors is distributed equally
between the three classes.
</FONT>

<P align="center"><FONT size="2">2</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With regard to dividends, no dividend on our common stock may be paid
unless, at the time of such payment, all accrued dividends on our Series&nbsp;D 8%
Cumulative Convertible Voting Preferred Stock have been paid, and we have on
hand cash and other liquid assets sufficient to pay in full, in cash, the
liquidation preference that would be payable to the holders of the preferred
stock, as if such liquidation preference were then payable. Subject to this
preference and the preferences that may be applicable to the holders of any
other class of our preferred stock, if any, the holders of our common stock are
entitled to receive ratably such lawful dividends as may be declared by the
Board of Directors.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of liquidation, dissolution or winding up of Spectrum, before
any distribution of our assets shall be made to or set apart for the holders of
our common stock, the holders of our Series&nbsp;D 8% Cumulative Convertible Voting
Preferred Stock shall be entitled to receive payment out of our assets in an
amount equal to the liquidation preference set forth in the Certificate of
Designation for the preferred stock. If the assets available for distribution
to stockholders exceed the aggregate amount of the liquidation preference with
respect to all shares of the preferred stock then outstanding, then the holders
of our common stock shall be entitled to receive, subject to the rights of the
holders of any other class of our preferred stock, if any, pro rata all of our
remaining assets available for distribution to our stockholders.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock has no preemptive or conversion rights, other
subscription rights, or redemption or sinking fund provisions. All outstanding
shares of our common stock are fully paid and nonassessable. The rights,
powers, preferences and privileges of holders of our common stock are subject
to, and may be adversely affected by, the rights of the holders of shares of
any series of preferred stock.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Stockholder Rights Plan</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;13, 2000, we adopted a Stockholder Rights Plan pursuant to
which we have distributed rights to purchase units of our Series&nbsp;B Junior
Participating Preferred Stock. The rights become exercisable upon the earlier
of ten days after a person or group of affiliated or associated persons has
acquired 20% or more of the outstanding shares of our common stock or ten
business days after a tender offer has commenced that would result in a person
or group beneficially owning 20% or more of our outstanding common stock, other
than pursuant to a transaction approved in advance by our Board of Directors.
The description and terms of the rights are set forth in a Rights Agreement
between us and U.S. Stock Transfer Corporation, as rights agent, filed with the
Securities and Exchange Commission on December&nbsp;26, 2000, as Exhibit&nbsp;4.1 to our
Form&nbsp;8-A.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Certain Provisions of Delaware Law and of the Company&#146;s Charter and
Bylaws</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>The following paragraphs summarize certain provisions of the Delaware
General Corporation Law and our Charter and Bylaws. The summary does not
purport to be complete and is subject to and qualified in its entirety by
reference to the DGCL and to our Charter and Bylaws, copies of which are on
file with the Securities and Exchange Commission.</I>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Certificate of Incorporation and Bylaws contain provisions that,
together with the ownership position of the officers, directors and their
affiliates, could discourage potential takeover attempts and make it more
difficult for stockholders to change management, which could adversely affect
the market price of our common stock.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Certificate of Incorporation limits the extent to which our directors
are personally liable to Spectrum and our stockholders, to the fullest extent
permitted by the Delaware General Corporation Law, or DGCL. The inclusion of
this provision in our Certificate of Incorporation may reduce the likelihood of
derivative litigation against directors and may discourage or deter
stockholders or management from bringing a lawsuit against directors for breach
of their duty of care.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Bylaws provide that special meetings of stockholders can be called
only by the Board of Directors, the Chairman of the Board of Directors or the
Chief Executive Officer. Stockholders are not permitted to call a special
meeting and cannot require the Board of Directors to call a special meeting.
There is no right of stockholders to act by written consent without a meeting,
unless the consent is unanimous. Any vacancy on the Board of Directors
resulting from death, resignation, removal or otherwise or newly created
directorships may be filled only by vote of the majority of directors then in
office, or by a sole remaining director. Our Bylaws establish advance notice
procedures with respect to stockholder proposals and the nomination of
candidates for election as directors, except for nominations made by or at the
direction of the board of directors or a committee of the board. Our Bylaws
also provide for a classified board. See &#147;Terms&#148; above.
</FONT>

<P align="center"><FONT size="2">3</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the &#147;business combination&#148; statute of the DGCL, an
anti-takeover law enacted in 1988. In general, Section&nbsp;203 of the DGCL
prohibits a publicly-held Delaware corporation from engaging in a &#147;business
combination&#148; with an &#147;interested stockholder,&#148; for a period of three years
after the date of the transaction in which a person became an &#147;interested
stockholder,&#148; unless:
</FONT>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&#149;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">prior to such date the board of directors of the corporation
approved either the &#147;business combination&#148; or the transaction which
resulted in the stockholder becoming an &#147;interested stockholder,&#148;</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&#149;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">upon consummation of the transaction which resulted in the
stockholder becoming an &#147;interested stockholder,&#148; the &#147;interested
stockholder&#148; owned at least 85% of the voting stock of the
corporation outstanding at the time the transaction commenced,
excluding for purposes of determining the number of shares
outstanding those shares owned (1)&nbsp;by persons who are directors and
also officers and (2)&nbsp;employee stock plans in which employee
participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender
or exchange offer, or</FONT></TD>
</TR>
<TR>
    <TD><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="1%" align="left" nowrap><FONT size="2">&#149;</FONT></TD>
    <TD width="3%"><FONT size="2">&nbsp;</FONT></TD>
    <TD width="93%"><FONT size="2">at or subsequent to such time the &#147;business combination&#148; is
approved by the board of directors and authorized at an annual or
special meeting of stockholders, and not by written consent, by the
affirmative vote of a least 66 2/3% of the outstanding voting stock
which is not owned by the &#147;interested stockholder.&#148;</FONT></TD>
</TR>
</TABLE>
<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A &#147;business combination&#148; includes mergers, stock or asset sales and other
transactions resulting in a financial benefit to the &#147;interested stockholders.&#148;
An &#147;interested stockholder&#148; is a person who, together with affiliates and
associates, owns (or within three years, did own) 15% or more of the
corporation&#146;s voting stock. Although Section&nbsp;203 permits us to elect not to be
governed by its provisions, we have not made this election. As a result of the
application of Section&nbsp;203, potential acquirers of Spectrum may be discouraged
from attempting to effect an acquisition transaction with us, thereby possibly
depriving holders of our securities of certain opportunities to sell or
otherwise dispose of such securities at above-market prices pursuant to such
transactions.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Transfer Agent and Registrar</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for the common stock is U.S. Stock
Transfer Corporation.
</FONT>

<!-- link2 "Item&nbsp;6. Indemnification of Directors and Officers." -->
<DIV align="left"><A NAME="005"></A></DIV>

<P align="left"><FONT size="2"><B>Item&nbsp;6. Indemnification of Directors and Officers.</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;102(b)(7) of the DGCL provides that a certificate of incorporation
may include a provision which eliminates or limits the personal liability of a
director to the corporation or its stockholders for monetary damages for breach
of fiduciary duty as a director, except for liability (i)&nbsp;for any breach of the
director&#146;s duty of loyalty to the company or its stockholders, (ii)&nbsp;for acts or
omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL, relating to
prohibited dividends or distributions or the repurchase or redemption of stock
or (iv)&nbsp;for any transaction from which the director derives an improper
personal benefit. Our Certificate of Incorporation includes such a provision.
As a result of this provision, Spectrum Pharmaceuticals and its stockholders
may be unable to obtain monetary damages from a director for breach of his or
her duty of care.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our bylaws provide for indemnification of our directors and officers to
the fullest extent permitted by law. Insofar as indemnification for liabilities
under the Securities Act may be permitted to our directors, officers or
controlling persons pursuant to our Certificate of Incorporation, bylaws and
the DGCL, we have been informed that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in such Act and is therefore unenforceable.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into agreements to indemnify our directors and executive
officers, in addition to the indemnification provided for in our bylaws. We
believe that these provisions and agreements are necessary to attract and
retain qualified directors and executive officers. Our bylaws also permit us
to secure insurance on behalf of any officer, director, employee or other agent
against any expense, liability or loss, regardless of whether the DGCL would
permit indemnification. We have liability insurance for our officers and
directors.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Amended and Restated 1997 Stock Incentive Plan limits the liability of
our directors and officers with duties under the Plan and indemnifies each of
our directors and officers with duties under the Plan, who was or is a party,
or is threatened to be made a party, to any threatened, pending or completed
proceeding, whether civil,
</FONT>
<P align="center"><FONT size="2">4</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>


<P align="left"><FONT size="2"> criminal, administrative or investigative, by reason of such person&#146;s
conduct in the performance of their duties under the Plan.
</FONT>

<!-- link2 "Item&nbsp;8. Exhibits" -->
<DIV align="left"><A NAME="006"></A></DIV>

<P align="left"><FONT size="2"><B>Item&nbsp;8. Exhibits</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Index to Exhibits on page 4.
</FONT>

<P align="center"><FONT size="2">5</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="007"></A></DIV>

<P align="center"><FONT size="2"><B>SIGNATURES</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the
registrant, Spectrum Pharmaceuticals, Inc., a Delaware corporation, certifies
that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form&nbsp;S-8 and has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Irvine, State of California, on this 24th day of June, 2003.
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="3" valign="top" align="left"><FONT size="2">SPECTRUM PHARMACEUTICALS, INC.</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
By:
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">/s/ Rajesh C. Shrotriya</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR>
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><HR size="1" noshade></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">Rajesh C. Shrotriya<br>
Chairman, Chief Executive Officer
and President</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
</TABLE>
</CENTER>
<!-- link1 "POWER OF ATTORNEY" -->
<DIV align="left"><A NAME="008"></A></DIV>

<P align="center"><FONT size="2"><B>POWER OF ATTORNEY</B>
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each person whose signature appears below hereby authorizes and appoints
Rajesh C. Shrotriya and John L. McManus, or either of them, as
attorneys-in-fact and agents with full power of substitution and
resubstitution, to sign on his behalf, individually and in the capacities
stated below, and to file any and all amendments, including post-effective
amendments, to this registration statement and other documents in connection
therewith, with the Securities and Exchange Commission, granting to said
attorneys-in-fact and agents full power and authority to perform any other act
on behalf of the undersigned required to be done in the premises.
</FONT>

<P align="left"><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities indicated as of June&nbsp;24, 2003.
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><FONT size="1"><B>Signature</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1"><B>Title</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD  align="center" valign="top"><FONT size="2">/s/ Rajesh C. Shrotriya
<HR size="1" noshade>
Rajesh C. Shrotriya, M.D.</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Chairman, Chief Executive Officer,
President and Director (principal
executive officer)
</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD  align="center" valign="top"><FONT size="2">/s/ John L. McManus
<HR size="1" noshade>
John L McManus</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Vice President, Strategic Planning and
Finance (principal financial officer)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">/s/ Michael P. McManus
<HR size="1" noshade>
Michael P. McManus</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Controller (principal accounting officer)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">/s/ Mark J. Glasky
<HR size="1" noshade>
Mark J. Glasky</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">/s/ Carol O&#146;Cleiracain
<HR size="1" noshade>
Carol O&#146;Cleiracain, Ph.D.</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">/s/ Paul H. Silverman
<HR size="1" noshade>
Paul H. Silverman, Ph.D., D.Sc</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">/s/ Armin M. Kessler
<HR size="1" noshade>
Armin M. Kessler</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">/s/ Ann C. Kessler
<HR size="1" noshade>
Ann C. Kessler, Ph.D.</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">/s/ Julius A. Vida
<HR size="1" noshade>
Julius A. Vida, Ph.D.</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Director</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">&nbsp;</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">6</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="009"></A></DIV>

<P align="center"><FONT size="2"><B>INDEX TO EXHIBITS</B>
</FONT>

<CENTER>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><FONT size="1"><B>EXHIBIT</B></FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">4.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Spectrum Pharmaceuticals, Inc. Amended and Restated 1997 Stock Incentive Plan
(Filed as Annex A to our Definitive Proxy Statement, as filed with the
Securities and Exchange Commission on May&nbsp;16, 2003 and incorporated herein by
reference.)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">5.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Opinion of Latham &#038; Watkins LLP</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">23.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Consent of Latham &#038; Watkins LLP (included in Exhibit&nbsp;5.1)</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">23.2</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Consent of Kelly &#038; Company</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">23.3</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Information Regarding Consent of Arthur Andersen LLP.</FONT></TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><FONT size="2">24</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Power of Attorney (included in the signature page to this Registration Statement)</FONT></TD>
</TR>
</TABLE>
</CENTER>
<P align="center"><FONT size="2">7</FONT>

</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "a90880sv8.htm", "description": "FORM S-8", "secsgml_size_bytes": 45797}]
{"company-data": {"conformed-name": "SPECTRUM PHARMACEUTICALS INC", "cik": "0000831547", "assigned-sic": "2834", "irs-number": "930979187", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-106427", "film-number": "03755482"}, "business-address": {"street1": "157 TECHNOLOGY DR", "city": "IRVINE", "state": "CA", "zip": "92618", "phone": "9497886700"}, "mail-address": {"street1": "157 TECHNOLOGY DR", "city": "IRVINE", "state": "CA", "zip": "92618"}, "former-company": [{"former-conformed-name": "NEOTHERAPEUTICS INC", "date-changed": "19960819"}, {"former-conformed-name": "AMERICUS FUNDING CORP", "date-changed": "19920703"}]}
Form S-8 for Spectrum
Table of Contents
As filed with the Securities and
Exchange Commission on June 24, 2003
Registration No. 333-_________
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SPECTRUM PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
93-079187
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification Number)
157 Technology Dr.
Irvine, California 92618
(Address of Principal Executive Offices including Zip Code)
SPECTRUM PHARMACEUTICALS, INC.
AMENDED AND RESTATED
1997 STOCK INCENTIVE PLAN
(Full Title of the Plan)
Rajesh C. Shrotriya
Copy to:
Chief Executive Officer and President
Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Alan W. Pettis
Latham & Watkins LLP
650 Town Center Drive, Twentieth Floor
Irvine, California 92618
(949) 788-6700
Costa Mesa, California 92626
(714) 540-1235
(Name, Address, Including Zip Code, and Telephone Number,
Including Area Code, of Agent for Service)
CALCULATION OF REGISTRATION FEE
Proposed
Proposed
Maximum
Amount
Maximum
Aggregate
Amount of
Title of Securities to
to be
Offering Price
Offering
Registration
be Registered
Registered
(1)(2)
Per Share
(3)
Price
(3)
Fee
Common stock par
value $0.001 per
share
1,199,000 shares
$
16.165
$
19,381,400
$
1,567.96
(1)
The Spectrum Pharmaceuticals, Inc. Amended and Restated 1997 Stock
Incentive Plan authorizes the issuance of an aggregate of 1,219,000
shares, par value $0.001 per share, of the Registrant's common stock, of
which 1,199,000 shares are being registered hereunder and 20,000 of which
have been previously registered.
(2)
In the event of a stock split, stock dividend, or similar transaction
involving the Registrant's common stock, in order to prevent dilution, the
number of shares registered hereby shall automatically be increased to
cover the additional shares in accordance with Rule 416(a) under the
Securities Act of 1933.
(3)
Estimated solely for the purpose of calculating the registration fee
pursuant to Rules 457(c) and 457(h) under the Securities Act of 1933 based
on the actual exercise price of options previously granted and the average of the high and low sales price of the Registrant's common
stock on the Nasdaq SmallCap Market on June 23, 2003 for the
remaining balance not previously granted.
Proposed issuances to commence as soon after the effective date of the Registration
Statement as practicable.
TABLE OF CONTENTS
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 4. Description of Securities
Item 6. Indemnification of Directors and Officers.
Item 8. Exhibits
SIGNATURES
POWER OF ATTORNEY
INDEX TO EXHIBITS
EXHIBIT 5.1
EXHIBIT 23.2
EXHIBIT 23.3
Table of Contents
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
We are not filing or including in this Form S-8 the information called for
in Part I of Form S-8 (by incorporation by reference or otherwise) in
accordance with the rules and regulations of the Securities and Exchange
Commission.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Registration of Additional Securities
Our Amended and Restated 1997 Stock Incentive Plan authorizes the issuance
of an aggregate of 1,219,000 shares of our common stock. We have previously
registered 20,000 shares (as adjusted to reflect a 25-for-1 reverse split of
our outstanding common stock that we effected on September 6, 2002) issuable
under the Plan by a registration statement on Form S-8 filed with the
Securities and Exchange Commission on June 30, 1997, Registration No.
333-30345. Under this registration statement, we are registering an additional
1,199,000 shares of our common stock issuable under the Plan. The contents of
the registration statement filed on June 30, 1997, are incorporated by
reference herein to the extent not modified or superseded thereby or by any
subsequently filed document that is incorporated by reference herein or
therein.
Experts
The consolidated financial statements of the Company as of December 31,
2002 and for the year ended December 31, 2002, incorporated by reference in
this registration statement have been audited by Kelly & Company, independent
public accountants, as indicated in their report with respect thereto, and are
included herein in reliance upon the authority of said firm as experts in
giving said report.
The consolidated financial statements of the Company as of December 31,
2001 and for the two years ended December 31, 2001 incorporated by reference in
this registration statement have been audited by Arthur Andersen LLP,
independent public accountants, as indicated in their report with respect
thereto, and are included herein in reliance upon the authority of said firm as
experts in giving said report. Arthur Andersen LLP has not consented to the
inclusion of their report in the registration statement, and in reliance upon
Rule 437a of the Securities Act, we have not therefore filed their consent.
Because Arthur Andersen LLP has not consented to the inclusion of their report
in the registration statement, it may become more difficult for you to seek
remedies against Arthur Andersen LLP in connection with any material
misstatement or omission that may be contained in our consolidated financial
statements and schedules for such periods. In particular, and without
limitation, you will not be able to recover against Arthur Andersen LLP under
Section 11 of the Securities Act for any untrue statement of a material fact
contained in the financial statements audited by Arthur Andersen LLP or any
omission of a material fact required to be statement in those financial
statements.
Item 4. Description of Securities
The following summary of the terms of our common stock does not purport to
be complete and is subject to and qualified in its entirety by reference to our
Charter and Bylaws, copies of which are on file with the Securities and
Exchange Commission.
We have authority to issue 50,000,000 shares of common stock, $.001 par
value per share. As of June 13, 2003, we had 3,108,100 shares of common stock
outstanding, held of record by approximately 377 stockholders.
Terms
Holders of our common stock are entitled to one vote per share on all
matters to be voted upon by the stockholders. The holders of common stock are
not entitled to cumulative voting rights with respect to election of directors,
and as a consequence, minority stockholders will not be able to elect directors
on the basis of their shares alone. Our board of directors is divided into
three classes, with the term of each class expiring every third year at the
annual meeting of stockholders. The number of directors is distributed equally
between the three classes.
2
Table of Contents
With regard to dividends, no dividend on our common stock may be paid
unless, at the time of such payment, all accrued dividends on our Series D 8%
Cumulative Convertible Voting Preferred Stock have been paid, and we have on
hand cash and other liquid assets sufficient to pay in full, in cash, the
liquidation preference that would be payable to the holders of the preferred
stock, as if such liquidation preference were then payable. Subject to this
preference and the preferences that may be applicable to the holders of any
other class of our preferred stock, if any, the holders of our common stock are
entitled to receive ratably such lawful dividends as may be declared by the
Board of Directors.
In the event of liquidation, dissolution or winding up of Spectrum, before
any distribution of our assets shall be made to or set apart for the holders of
our common stock, the holders of our Series D 8% Cumulative Convertible Voting
Preferred Stock shall be entitled to receive payment out of our assets in an
amount equal to the liquidation preference set forth in the Certificate of
Designation for the preferred stock. If the assets available for distribution
to stockholders exceed the aggregate amount of the liquidation preference with
respect to all shares of the preferred stock then outstanding, then the holders
of our common stock shall be entitled to receive, subject to the rights of the
holders of any other class of our preferred stock, if any, pro rata all of our
remaining assets available for distribution to our stockholders.
Our common stock has no preemptive or conversion rights, other
subscription rights, or redemption or sinking fund provisions. All outstanding
shares of our common stock are fully paid and nonassessable. The rights,
powers, preferences and privileges of holders of our common stock are subject
to, and may be adversely affected by, the rights of the holders of shares of
any series of preferred stock.
Stockholder Rights Plan
On December 13, 2000, we adopted a Stockholder Rights Plan pursuant to
which we have distributed rights to purchase units of our Series B Junior
Participating Preferred Stock. The rights become exercisable upon the earlier
of ten days after a person or group of affiliated or associated persons has
acquired 20% or more of the outstanding shares of our common stock or ten
business days after a tender offer has commenced that would result in a person
or group beneficially owning 20% or more of our outstanding common stock, other
than pursuant to a transaction approved in advance by our Board of Directors.
The description and terms of the rights are set forth in a Rights Agreement
between us and U.S. Stock Transfer Corporation, as rights agent, filed with the
Securities and Exchange Commission on December 26, 2000, as Exhibit 4.1 to our
Form 8-A.
Certain Provisions of Delaware Law and of the Company's Charter and
Bylaws
The following paragraphs summarize certain provisions of the Delaware
General Corporation Law and our Charter and Bylaws. The summary does not
purport to be complete and is subject to and qualified in its entirety by
reference to the DGCL and to our Charter and Bylaws, copies of which are on
file with the Securities and Exchange Commission.
Our Certificate of Incorporation and Bylaws contain provisions that,
together with the ownership position of the officers, directors and their
affiliates, could discourage potential takeover attempts and make it more
difficult for stockholders to change management, which could adversely affect
the market price of our common stock.
Our Certificate of Incorporation limits the extent to which our directors
are personally liable to Spectrum and our stockholders, to the fullest extent
permitted by the Delaware General Corporation Law, or DGCL. The inclusion of
this provision in our Certificate of Incorporation may reduce the likelihood of
derivative litigation against directors and may discourage or deter
stockholders or management from bringing a lawsuit against directors for breach
of their duty of care.
Our Bylaws provide that special meetings of stockholders can be called
only by the Board of Directors, the Chairman of the Board of Directors or the
Chief Executive Officer. Stockholders are not permitted to call a special
meeting and cannot require the Board of Directors to call a special meeting.
There is no right of stockholders to act by written consent without a meeting,
unless the consent is unanimous. Any vacancy on the Board of Directors
resulting from death, resignation, removal or otherwise or newly created
directorships may be filled only by vote of the majority of directors then in
office, or by a sole remaining director. Our Bylaws establish advance notice
procedures with respect to stockholder proposals and the nomination of
candidates for election as directors, except for nominations made by or at the
direction of the board of directors or a committee of the board. Our Bylaws
also provide for a classified board. See "Terms" above.
3
Table of Contents
We are subject to the "business combination" statute of the DGCL, an
anti-takeover law enacted in 1988. In general, Section 203 of the DGCL
prohibits a publicly-held Delaware corporation from engaging in a "business
combination" with an "interested stockholder," for a period of three years
after the date of the transaction in which a person became an "interested
stockholder," unless:
•
prior to such date the board of directors of the corporation
approved either the "business combination" or the transaction which
resulted in the stockholder becoming an "interested stockholder,"
•
upon consummation of the transaction which resulted in the
stockholder becoming an "interested stockholder," the "interested
stockholder" owned at least 85% of the voting stock of the
corporation outstanding at the time the transaction commenced,
excluding for purposes of determining the number of shares
outstanding those shares owned (1) by persons who are directors and
also officers and (2) employee stock plans in which employee
participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender
or exchange offer, or
•
at or subsequent to such time the "business combination" is
approved by the board of directors and authorized at an annual or
special meeting of stockholders, and not by written consent, by the
affirmative vote of a least 66 2/3% of the outstanding voting stock
which is not owned by the "interested stockholder."
A "business combination" includes mergers, stock or asset sales and other
transactions resulting in a financial benefit to the "interested stockholders."
An "interested stockholder" is a person who, together with affiliates and
associates, owns (or within three years, did own) 15% or more of the
corporation's voting stock. Although Section 203 permits us to elect not to be
governed by its provisions, we have not made this election. As a result of the
application of Section 203, potential acquirers of Spectrum may be discouraged
from attempting to effect an acquisition transaction with us, thereby possibly
depriving holders of our securities of certain opportunities to sell or
otherwise dispose of such securities at above-market prices pursuant to such
transactions.
Transfer Agent and Registrar
The transfer agent and registrar for the common stock is U.S. Stock
Transfer Corporation.
Item 6. Indemnification of Directors and Officers.
Section 102(b)(7) of the DGCL provides that a certificate of incorporation
may include a provision which eliminates or limits the personal liability of a
director to the corporation or its stockholders for monetary damages for breach
of fiduciary duty as a director, except for liability (i) for any breach of the
director's duty of loyalty to the company or its stockholders, (ii) for acts or
omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii) under Section 174 of the DGCL, relating to
prohibited dividends or distributions or the repurchase or redemption of stock
or (iv) for any transaction from which the director derives an improper
personal benefit. Our Certificate of Incorporation includes such a provision.
As a result of this provision, Spectrum Pharmaceuticals and its stockholders
may be unable to obtain monetary damages from a director for breach of his or
her duty of care.
Our bylaws provide for indemnification of our directors and officers to
the fullest extent permitted by law. Insofar as indemnification for liabilities
under the Securities Act may be permitted to our directors, officers or
controlling persons pursuant to our Certificate of Incorporation, bylaws and
the DGCL, we have been informed that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in such Act and is therefore unenforceable.
We have entered into agreements to indemnify our directors and executive
officers, in addition to the indemnification provided for in our bylaws. We
believe that these provisions and agreements are necessary to attract and
retain qualified directors and executive officers. Our bylaws also permit us
to secure insurance on behalf of any officer, director, employee or other agent
against any expense, liability or loss, regardless of whether the DGCL would
permit indemnification. We have liability insurance for our officers and
directors.
Our Amended and Restated 1997 Stock Incentive Plan limits the liability of
our directors and officers with duties under the Plan and indemnifies each of
our directors and officers with duties under the Plan, who was or is a party,
or is threatened to be made a party, to any threatened, pending or completed
proceeding, whether civil,
4
Table of Contents
criminal, administrative or investigative, by reason of such person's
conduct in the performance of their duties under the Plan.
Item 8. Exhibits
See Index to Exhibits on page 4.
5
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
registrant, Spectrum Pharmaceuticals, Inc., a Delaware corporation, certifies
that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-8 and has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Irvine, State of California, on this 24th day of June, 2003.
SPECTRUM PHARMACEUTICALS, INC.
By:
/s/ Rajesh C. Shrotriya
Rajesh C. Shrotriya
Chairman, Chief Executive Officer
and President
POWER OF ATTORNEY
Each person whose signature appears below hereby authorizes and appoints
Rajesh C. Shrotriya and John L. McManus, or either of them, as
attorneys-in-fact and agents with full power of substitution and
resubstitution, to sign on his behalf, individually and in the capacities
stated below, and to file any and all amendments, including post-effective
amendments, to this registration statement and other documents in connection
therewith, with the Securities and Exchange Commission, granting to said
attorneys-in-fact and agents full power and authority to perform any other act
on behalf of the undersigned required to be done in the premises.
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities indicated as of June 24, 2003.
Signature
Title
/s/ Rajesh C. Shrotriya
Rajesh C. Shrotriya, M.D.
Chairman, Chief Executive Officer,
President and Director (principal
executive officer)
/s/ John L. McManus
John L McManus
Vice President, Strategic Planning and
Finance (principal financial officer)
/s/ Michael P. McManus
Michael P. McManus
Controller (principal accounting officer)
/s/ Mark J. Glasky
Mark J. Glasky
Director
/s/ Carol O'Cleiracain
Carol O'Cleiracain, Ph.D.
Director
/s/ Paul H. Silverman
Paul H. Silverman, Ph.D., D.Sc
Director
/s/ Armin M. Kessler
Armin M. Kessler
Director
/s/ Ann C. Kessler
Ann C. Kessler, Ph.D.
Director
/s/ Julius A. Vida
Julius A. Vida, Ph.D.
Director
6
Table of Contents
INDEX TO EXHIBITS
EXHIBIT
4.1
Spectrum Pharmaceuticals, Inc. Amended and Restated 1997 Stock Incentive Plan
(Filed as Annex A to our Definitive Proxy Statement, as filed with the
Securities and Exchange Commission on May 16, 2003 and incorporated herein by
reference.)
5.1
Opinion of Latham & Watkins LLP
23.1
Consent of Latham & Watkins LLP (included in Exhibit 5.1)
23.2
Consent of Kelly & Company
23.3
Information Regarding Consent of Arthur Andersen LLP.
24
Power of Attorney (included in the signature page to this Registration Statement)
7